南通大学学报（医学版）
南通大學學報（醫學版）
남통대학학보（의학판）
JOURNAL OF NANTONG UNIVERSITY(MEDICAL SCIENCES)
2014年
4期
251-253,254
,共4页
非小细胞肺癌%基因%化疗药物%ATP-TCA%免疫组织化学
非小細胞肺癌%基因%化療藥物%ATP-TCA%免疫組織化學
비소세포폐암%기인%화료약물%ATP-TCA%면역조직화학
non-small-cell lung carncer%gene%chemotherapeutic drug%ATP-bioluminescence assay%immunohistochemistry
目的：探讨非小细胞肺癌组织乳腺癌易感基因1(breast cancer susceptibility gene1，BRCA1)、切除修复交叉互补基因1(excision repair cross-complementing gene1，ERCC1)、核苷酸还原酶 M1亚基(ribonucleotide reductase M1， RRM1)蛋白表达与肿瘤体外药敏的相关性，为非小细胞肺癌个体化治疗提供预测指标。方法：收集32例非小细胞肺癌患者手术切除的新鲜标本，采用ATP-TCA方法检测紫杉醇、顺铂、吉西他滨体外药敏；采用免疫组化PV方法检测BR-CA1、ERCC1、RRM1蛋白表达。结果：BRCA1高表达18例(56.2％)，低表达14例(43.8％)，BRCA1高表达组紫杉醇有效13例(72.2％)，BRCA1低表达组有效4例(28.6％)(P<0.05)；ERCC1高表达13例(40.6％)，低表达19例(59.4％)，ERCC1高表达组顺铂有效2例(15.4％)，ERCC1低表达组有效11例(57.9％)(P<0.05)；RRM1高表达15例(46.9%)，低表达17例(53.1%)， RRM1高表达组吉西他滨有效3例(20.0%)，RRM1低表达组有效10例(58.8%)(P<0.05)。结论：BRCA1、ERCC1、RRM1蛋白表达水平和紫杉醇、顺铂、吉西他滨体外药物敏感性具有相关性，联合检测为非小细胞肺癌筛选化疗药物提供更加可靠的依据。
目的：探討非小細胞肺癌組織乳腺癌易感基因1(breast cancer susceptibility gene1，BRCA1)、切除脩複交扠互補基因1(excision repair cross-complementing gene1，ERCC1)、覈苷痠還原酶 M1亞基(ribonucleotide reductase M1， RRM1)蛋白錶達與腫瘤體外藥敏的相關性，為非小細胞肺癌箇體化治療提供預測指標。方法：收集32例非小細胞肺癌患者手術切除的新鮮標本，採用ATP-TCA方法檢測紫杉醇、順鉑、吉西他濱體外藥敏；採用免疫組化PV方法檢測BR-CA1、ERCC1、RRM1蛋白錶達。結果：BRCA1高錶達18例(56.2％)，低錶達14例(43.8％)，BRCA1高錶達組紫杉醇有效13例(72.2％)，BRCA1低錶達組有效4例(28.6％)(P<0.05)；ERCC1高錶達13例(40.6％)，低錶達19例(59.4％)，ERCC1高錶達組順鉑有效2例(15.4％)，ERCC1低錶達組有效11例(57.9％)(P<0.05)；RRM1高錶達15例(46.9%)，低錶達17例(53.1%)， RRM1高錶達組吉西他濱有效3例(20.0%)，RRM1低錶達組有效10例(58.8%)(P<0.05)。結論：BRCA1、ERCC1、RRM1蛋白錶達水平和紫杉醇、順鉑、吉西他濱體外藥物敏感性具有相關性，聯閤檢測為非小細胞肺癌篩選化療藥物提供更加可靠的依據。
목적：탐토비소세포폐암조직유선암역감기인1(breast cancer susceptibility gene1，BRCA1)、절제수복교차호보기인1(excision repair cross-complementing gene1，ERCC1)、핵감산환원매 M1아기(ribonucleotide reductase M1， RRM1)단백표체여종류체외약민적상관성，위비소세포폐암개체화치료제공예측지표。방법：수집32례비소세포폐암환자수술절제적신선표본，채용ATP-TCA방법검측자삼순、순박、길서타빈체외약민；채용면역조화PV방법검측BR-CA1、ERCC1、RRM1단백표체。결과：BRCA1고표체18례(56.2％)，저표체14례(43.8％)，BRCA1고표체조자삼순유효13례(72.2％)，BRCA1저표체조유효4례(28.6％)(P<0.05)；ERCC1고표체13례(40.6％)，저표체19례(59.4％)，ERCC1고표체조순박유효2례(15.4％)，ERCC1저표체조유효11례(57.9％)(P<0.05)；RRM1고표체15례(46.9%)，저표체17례(53.1%)， RRM1고표체조길서타빈유효3례(20.0%)，RRM1저표체조유효10례(58.8%)(P<0.05)。결론：BRCA1、ERCC1、RRM1단백표체수평화자삼순、순박、길서타빈체외약물민감성구유상관성，연합검측위비소세포폐암사선화료약물제공경가가고적의거。
Obj ective: To explore the relationship between BRCA1、ERCC1、RRM1 protein expressions of non-small-cell lung cancer and sensitivity of the cancer to chemotherapeutic drug in vitro, and provide prognostic markers to guide individu-al chemotherapy in non-small-cell lung cancer field. Methods: 32 fresh operative non-small-cell lung cancer samples were collected and immediately were used to be tested the sensitivity to paclitaxel,cisplatin,gemcitabine with the method of ATP-tumor chemosensitivity assay;detected expressions of BRCA1, ERCC1, RRM1 in 32 cases of non-small-cell lung cancer paraffin-embedded pathological specimens by means of immunohistochemical analysis(PV method). Results: There were 18 (56.3%)cases with the high level of BRCA1 protein expression, and still another 14 cases(43.8%) with the low level of BR-CA1 protein expression, there were 13 cases(72.2%) with sensitive to paclitaxel in the high level of BRCA1 protein expres-sion group,and 4 sensitive cases (28.6%) in the low level of BRCA1 protein expression group (P<0.05). There were 13cases (40.6%) with the high level of ERCC1 protein expression, and still another 19 cases(59.4%) with the low level of ERCC1 protein expression , there were 2 cases ( 15 . 4%) with sensitive to cisplatin in the high level of ERCC1 protein expression group,and 11 sensitive cases(57.9%) in the low level of ERCC1 protein expression group(P<0.05). There were 15 cases (46.9%) with the high level of RRM1 protein expression, and still another 17 cases(46.9%) with the low level of RRM1 protein expression, there were 3 cases(20.0%) with sensitive to gemcitabine in the high level of RRM1 protein expression group,and 10 sensitive cases(58.8%) in the low level of RRM1 protein expression group(P<0.05).Conclusion: There is a relevance between BRCA1、ERCC1、RRM1 protein expressions of non-small-cell lung cancer and its sensitivity to paclitax-el、cisplatin、gemcitabine in vitro. A combined test with this two methods may be useful in providing more reliable evidence to choose chemotherapeutic drug in non-small-cell lung cancer field.
